英特集团：子公司完成对华通医药收购

Group 1 - The core point of the news is that Yingte Group has completed the equity transfer of Huatuo Pharmaceutical, making it a wholly-owned subsidiary, which aligns with the company's strategic planning and business development needs [1] - Huatuo Pharmaceutical has a significant advantage in the grassroots public medical market, and its retail segment, Huatuo Chain, is among the top 100 pharmaceutical retail enterprises, creating high synergy with the company's existing business [1] - This transaction is expected to enhance the company's market share in Zhejiang's pharmaceutical wholesale and retail business, improving bargaining power with upstream suppliers and influence over end consumers [1] Group 2 - Yingte Group reported total operating revenue of 24.963 billion yuan for the first three quarters of 2025, a year-on-year increase of 0.75% [2] - The net profit attributable to the parent company for the same period was 323 million yuan, a year-on-year decrease of 9.15% [2] - In the third quarter, the company achieved operating revenue of 8.334 billion yuan, a year-on-year increase of 2.05%, while the net profit attributable to the parent company was 73.9815 million yuan, down 24.19% year-on-year [2]